Mast cell activation syndrome: Current understanding and research needs.
Castells M., Giannetti MP., Hamilton MJ., Novak P., Pozdnyakova O., Nicoloro-SantaBarbara J., Jennings SV., Francomano C., Kim B., Glover SC., Galli SJ., Maitland A., White A., Abonia JP., Slee V., Valent P., Butterfield JH., Carter M., Metcalfe DD., Akin C., Lyons JJ., Togias A., Wheatley L., Milner JD.
Mast cell activation syndrome (MCAS) is a term applied to several clinical entities that have gained increased attention from patients and medical providers. Although several descriptive publications about MCAS exist, there are many gaps in knowledge, resulting in confusion about this clinical syndrome. Whether MCAS is a primary syndrome or exists as a constellation of symptoms in the context of known inflammatory, allergic, or clonal disorders associated with systemic mast cell activation is not well understood. More importantly, the underlying mechanisms and pathways that lead to mast cell activation in MCAS patients remain to be elucidated. Here we summarize the known literature, identify gaps in knowledge, and highlight research needs. Covered topics include contextualization of MCAS and MCAS-like endotypes and related diagnostic evaluations; mechanistic research; management of typical and refractory symptoms; and MCAS-specific education for patients and health care providers.